DEFJ Converts Preferred Shares, Diluting TransCode’s Capital & Unlocking Liquidity

Insider Conversion Signals a Shift in Capital Structure

The August 3, 2026 filing from DEFJ, LLC marks a significant conversion of the company’s Series A and Series B non‑voting convertible preferred shares into common stock. By exchanging roughly 1,181.39 shares of Series A and 202.06 shares of Series B for 13,834,441 new common shares, DEFJ is effectively diluting its own ownership stake while simultaneously unlocking liquidity. The move is timed just before the company’s 8‑K report on a second amendment to its certificate of designation, which removed a 60‑day notice requirement on beneficial ownership changes—an action that may ease future conversions.

What This Means for Investors

For shareholders, the conversion introduces a sizable dilution of existing shares, pushing the post‑transaction ownership back to about 12,113,899 common shares. Given TransCode’s current market cap of roughly $4.3 million and a flat or declining stock price (down 14 % week‑to‑week and 45 % month‑to‑month), the infusion of common shares may dilute earnings per share further and could weigh on short‑term price appreciation.

On the upside, the conversion frees up capital that DEFJ can redeploy, potentially funding research, clinical trials, or strategic acquisitions—a common practice for biotech firms seeking to accelerate product pipelines. The fact that the transaction price (around $4.27) is close to the market price suggests that DEFJ is not seeking to sell shares at a discount, indicating confidence in the company’s valuation.

DEFJ, LLC: A Profile of the Investor

DEFJ, LLC is a Delaware limited liability company wholly owned by Conjoint Inc., which in turn is owned by Honglad Limited, ENSO Resources Limited, and ultimately CK Life Sciences International Holdings, Inc. This multi‑layered structure is typical of institutional investors that manage portfolios through holding entities. Historically, DEFJ has maintained sizable holdings in both Series A and Series B preferred shares, with no recorded sales of these instruments in the past filing cycle, suggesting a long‑term investment horizon. The recent conversion indicates a strategic realignment—possibly a response to the company’s evolving capital needs or a desire to simplify the ownership structure ahead of a potential IPO or partnership.

Broader Insider Activity

The current filing shows a single buy transaction by DEFJ, while the company‑wide insider activity records only holdings—no additional purchases or sales by other insiders on August 5. This concentration of activity around DEFJ underscores the importance of monitoring the company’s preferred‑stock holders. Investors should watch for subsequent disclosures from CKLS or its subsidiaries, as their “section 16” status may change the effective ownership of the converted shares.

Takeaway

TransCode’s preferred‑stock conversion is a double‑edged sword: it provides liquidity for a major shareholder while diluting the equity base. For investors, the key questions are whether the company will use the freed capital to generate value that offsets the dilution, and whether the removal of the 60‑day notice requirement will invite additional conversions in the future. Keeping an eye on DEFJ’s future filings and any changes in CKLS’s beneficial ownership status will be essential for assessing the long‑term impact on TransCode’s stock performance.

Transaction Summary